Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy
It isn’t just the cutting-edge science. Novartis’ landmark approval also highlights regulatory and reimbursement innovation and also may set the rules that the next wave of cell and gene therapies have to follow.
You may also be interested in...
Much like Genzyme’s Ceredase did two decades ago, Novartis’ Zolgensma is setting a new pricing benchmark. The first million-dollar product is launching in the US and it will actually cost more than $2 million.
US launch of gene therapy Luxturna could set tone for attention to extremely high priced therapies in 2018. So far, company seems to be doing things right.
Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.